Product
Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
Anhui Zhifei Longcom Biologic Pharmacy co. Ltd.Status: Recruiting, Estimated PCD: 2023-07-30
1 clinical trial
1 indication